ArticlePakistan journal of medical sciences2025
Efficacy of Zhibitai combined with Atorvastatin on blood lipid and inflammation in patients with coronary heart disease.
Article in Pakistan journal of medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the efficacy and safety of Zhibitai combined with atorvastatin on blood lipid and inflammation. Method: This was a retrospective study which included eighty-five patients with coronary heart disease (CHD) with dyslipidemia in the Affiliated Hospital of Hebei University, from July 2022 to January 2024. They were divided into two groups according to the random number table, the atorvastatin monotherapy group (n=37) and the combination treatment group (n=48). Observation of changes in blood lipids, inflammatory mediators and incidence of adverse reactions were noted. Results: The levels of TC, LDL-C, and TG in both groups were significantly reduced compared to pre-treatment (p<0.05. The combination treatment group showed more significant decrease than the monotherapy group at four and 12 weeks of treatment (p<0.05); Both groups showed significant increase in HDL-C levels compared to pre-treatment (p<0.05), at week 12 of treatment, the combination treatment group showed more significant increase compared to the monotherapy group (p<0.05); Both groups can significantly reduce hs-CRP and IL-6(p<0.05); IL-6 was significantly reduced in the combination treatment group at four and 12 weeks of treatment compared to the monotherapy group (p<0.05); The decrease in hs-CRP in the combination treatment group was more significant than the monotherapy group after 12 weeks of treatment (p<0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups (p>0.05). Conclusion: Zhibitai combined with atorvastatin can effectively improve the lipid composition of patients with CHD, reduce inflammatory reactions, and have good safety.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.